News
We recently published a list of 15 Stocks That Stole The Show Last Week. In this article, we are going to take a look at ...
We recently published a list of These 10 Stocks Are On Fire Right Now. In this article, we are going to take a look at where ...
The study suggests a need for novel therapeutic approaches for patients with refractory disease or early relapse following CAR T-cell therapy. Despite limitations, BsAbs are considered safe and ...
The first part of the phase 2/3 study enrolled 40 people with relapsed or refractory diffuse large B cell lymphoma (DLBCL). Participants received one of three doses of zilovertamab vedotin in ...
DiPersio is senior author of the team’s published report in Blood, titled “Phase 1/2 Trial of Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell malignancies.” ...
At a pre-planned analysis, zilovertamab vedotin 1.75 mg/kg in combination with R-GemOx achieved a 56.3% objective response rate (ORR) in patients with relapsed or refractory DLBCL (n=16), with ...
and in patients with refractory chronic cough (RCC), today announced additional analyses from the Phase 2a RIVER trial of Haduvio for the treatment of patients with RCC (N=66). In March 2025 ...
GenTLE is a Phase I/IIa multi-center, open-label trial being conducted in the U.S. to evaluate the safety, tolerability and exploratory signs of efficacy of AMT-260 in individuals with refractory ...
CSIR NBRI Recruitment 2025: The CSIR-National Botanical Research Institute (NBRI) has released recruitment notification for Technical Assistant, Technician, Junior Secretariat Assistant (Finance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results